

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: NDA 20375/S004

CHEMISTRY REVIEW(S)

OCT - 4 1995

CHEMIST'S REVIEW

1. ORGANIZATION 2. NDA NUMBER
DMEDP, HFD-510 20-375

3. NAME AND ADDRESS OF APPLICANT 4. SUPPLEMENT
3M Pharmaceuticals NUMBER, DATE
3M Center, Bldg. 270-3A-01 Supplement
Saint Paul, Minnesota 55144-1000 S004
6. NAME OF THE DRUG 7. NONPROPRIETARY NAME 4-13-95

Climara Estradiol Trans-dermal System 9. AMENDMENTS/
REPORTS, DATE

8. SUPPLEMENT PROVIDES FOR:
Modifications of methods for in-process testing of estradiol rollstock during manufacture of the drug product, as described in 3M's DMF

10. PHARMACOLOGICAL CATEGORY 11. HOW DISPENSED 10. RELATED
Estrogen replacement RX OTC IND/NDA/DMF
X DMF

13. DOSAGE FORM 14. PCTENCY
Transdermal patch 3.9 and 7.8 mg/patch

15. CHEMICAL NAME AND STRUCTURE
C₁₈H₂₄O₂
MW = 272.39
Estra-1,3,5(10)-triene-3,17-diol, (17beta)-

16. COMMENTS
Coated rollstock is the intermediate material in the manufacture of the drug product, and is subject to in-process testing (See NDA Chemistry Review #1, 04-Mar-94). This Supplement provides for modifications in methods for some in-process testing. Chemistry, manufacturing and controls information for this NDA is contained in 3M Pharmaceuticals' DMF. An Amendment has been submitted to the DMF (on 13-Apr-95) to describe the testing modifications, and this DMF Amendment has been submitted for review as a "Changes Being Effected" Supplement to the NDA. Information in the DMF Amendment is reviewed in Chemistry Review #3 for DMF (completed on 04-Oct-95).

17. CONCLUSIONS AND RECOMMENDATIONS
The modifications in the methods for in-process testing of estradiol laminate during manufacture of the drug product are Acceptable. The Supplement can be approved.

18. REVIEWER
NAME SIGNATURE DATE COMPLETED
Helen W. Davies, Ph.D. [Signature] 10/04/95

DISTRIBUTION; ORIGINAL JACKET REVIEWER DIVISION FILE

R/D initialed by: H. Davies, designated team leader
wp N20375S4 10/04/95

CHEMISTRY REVIEW OF DMF

DMF

Division: HFD-510
Chemistry Review # 3
Date Completed: 04-Oct-95

Name and Address of Applicant:

3M Pharmaceuticals Division
3M Health Care
Building 270-3A-01 3M Center
Saint Paul, Minnesota 55144-1000

Initial Submission: August 31, 1992


Amendment: April 13, 1995

Related Documents: See Chemistry Review # 2 (28-Nov-94).

Remarks: Reviewed for NDA 20-375 (Climara (Estradiol transdermal system), 3M Pharmaceuticals)
This DMF contains all CMC information for NDA 20-375, except labeling. The Amendment describes changes in methods for the in-process testing of estradiol rollstock, which is performed during manufacture of the drug product.

Conclusions and Recommendation:

The modifications in the in-process testing are acceptable. The DMF remains satisfactory for support of NDA 20-375.


Helen W. Davies, Ph.D.
Review Chemist

cc: NDA 20-375 orig.
DMF # 9841 (2 copies)
HFD-510
HFD-510/HDavies

*H. Davies
designated team leader
10/04/95*